More extensive multicenter studies are needed to validate the diagnostic utility of CD79A and IL7R mRNA levels in CSF for detecting CNS involvement in B-ALL and to investigate the potential of these biomarkers to predict CNS relapses or response to therapy. This evidence concerns the gene CD79A and precursor B-cell acute lymphoblastic leukemia.